Medical Devices Investors & VC Firms in Switzerland

90 firms in this list, with a median first check of $648K. 27 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
MI MIG Capital AG KSAKJKMK25 people	88🔒	Munich	DE	Seed–Series A	$1.1M – $10.8M	+ Add to CRM
BE Beyond Capital Partners CDKBFHDD25 people · Leads rounds	88🔒	Frankfurt am Main	DE	Growth	—	+ Add to CRM
AN Ananda Impact Ventures JWLHSZZP15 people · Leads rounds	88🔒	Munich	DE	Pre-Seed–Series B	$540K – $3.2M	+ Add to CRM
BO BONVENTURE ALBJESHG21 people · Leads rounds	88🔒	München	DE	Seed–Series A	$1.1M – $2.7M	+ Add to CRM
AP Apollo Health Ventures ABNROMAB25 people · Leads rounds	88🔒	Berlin	DE	Seed–Series A	—	+ Add to CRM
UN United Founders RVVHCPDZ26 people	88🔒	Senningerberg	LU	—	—	+ Add to CRM
IN Invivo Capital Partners AFLPTLJM13 people	88🔒	Barcelona	ES	Pre-Seed–Series A	$2.2M – $4.3M	+ Add to CRM
AU Auriga Partners JCCLGRMC16 people	88🔒	Paris	FR	Seed–Growth	$540K – $5.4M	+ Add to CRM
XG XGEN Venture DSFDPFSV21 people	88🔒	Milan	IT	Pre-Seed–Series A	—	+ Add to CRM
BO Boehringer Ingelheim Venture Fund SEMHBHMB16 people	88🔒	Ingelheim am Rhein	DE	Seed–Growth	$16.2M	+ Add to CRM
DE Delin Ventures ILJHMSRB17 people	88🔒	London	GB	Pre-Seed–Seed	$216K – $2.2M	+ Add to CRM
LB LBBW Venture Capital GmbH AVFMCLMN9 people	88🔒	Stuttgart	DE	Seed–Series A	$540K – $3.2M	+ Add to CRM
PA PAI Partners AAKBAAWP13 people	88🔒	Paris	FR	Growth–Late Stage	$108M – $324M	+ Add to CRM
KI Kinled Holding PA1 person · Leads rounds	88🔒	Hong Kong	AT	Seed–Series A	—	+ Add to CRM
AM AMR Action Fund HSMHJGBB13 people · Leads rounds	88🔒	Boston	US	Seed–Growth	—	+ Add to CRM
VI VIVES Partners AVPDSSYV5 people	88🔒	Wavre	BE	Seed–Growth	$108K – $7.6M	+ Add to CRM
SK SKion FRSKDBRH9 people · Leads rounds	88🔒	Bad Homburg	DE	Growth	—	+ Add to CRM
AE Aescap Life Sciences PDAMBJGH14 people	88🔒	Amsterdam	NL	Series A–Growth	—	+ Add to CRM
EL Elysia Capital MLSBFMLA7 people	88🔒	Turin	IT	—	—	+ Add to CRM
CA Catalpa Ventures CGSRTGWE10 people · Leads rounds	88🔒	Grevenmacher	LU	Pre-Seed–Series A	$330K – $1.6M	+ Add to CRM
NO Novalis Biotech JVWVBRCB7 people	88🔒	Ghent	BE	Pre-Seed–Series A	—	+ Add to CRM
RO Rosetta Capital Ltd. JHKMMFDL8 people	88🔒	Oxford	GB	Growth–Late Stage	—	+ Add to CRM
TA Target Partners BVDTJWMK7 people	88🔒	Munich	DE	Seed–Late Stage	$1.1M – $3.2M	+ Add to CRM
SE Sectoral Asset Management FBGDMSMM8 people	88🔒	Montreal	CA	Series B–Late Stage	—	+ Add to CRM

MIG Capital AG

MunichSeed–Series A$1.1M – $10.8M

KSAKJKMK25 people

Beyond Capital Partners

Frankfurt am MainGrowth

CDKBFHDD25 people

Ananda Impact Ventures

MunichPre-Seed–Series B$540K – $3.2M

JWLHSZZP15 people

BONVENTURE

MünchenSeed–Series A$1.1M – $2.7M

ALBJESHG21 people

Apollo Health Ventures

BerlinSeed–Series A

ABNROMAB25 people

United Founders

Senningerberg

RVVHCPDZ26 people

Invivo Capital Partners

BarcelonaPre-Seed–Series A$2.2M – $4.3M

AFLPTLJM13 people

Auriga Partners

ParisSeed–Growth$540K – $5.4M

JCCLGRMC16 people

XGEN Venture

MilanPre-Seed–Series A

DSFDPFSV21 people

Boehringer Ingelheim Venture Fund

Ingelheim am RheinSeed–Growth$16.2M

SEMHBHMB16 people

Delin Ventures

LondonPre-Seed–Seed$216K – $2.2M

ILJHMSRB17 people

LBBW Venture Capital GmbH

StuttgartSeed–Series A$540K – $3.2M

AVFMCLMN9 people

PAI Partners

ParisGrowth–Late Stage$108M – $324M

AAKBAAWP13 people

Kinled Holding

Hong KongSeed–Series A

PA1 person

AMR Action Fund

BostonSeed–Growth

HSMHJGBB13 people

VIVES Partners

WavreSeed–Growth$108K – $7.6M

AVPDSSYV5 people

SKion

Bad HomburgGrowth

FRSKDBRH9 people

Aescap Life Sciences

AmsterdamSeries A–Growth

PDAMBJGH14 people

Elysia Capital

Turin

MLSBFMLA7 people

Catalpa Ventures

GrevenmacherPre-Seed–Series A$330K – $1.6M

CGSRTGWE10 people

Novalis Biotech

GhentPre-Seed–Series A

JVWVBRCB7 people

Rosetta Capital Ltd.

OxfordGrowth–Late Stage

JHKMMFDL8 people

Target Partners

MunichSeed–Late Stage$1.1M – $3.2M

BVDTJWMK7 people

Sectoral Asset Management

MontrealSeries B–Late Stage

FBGDMSMM8 people

Data sourced from public filings and firms' own websites — see our methodology.